KRAS mutation as a predictor of insufficient trastuzumab efficacy and poor prognosis in HER2-positive advanced gastric cancer
暂无分享,去创建一个
D. Takahari | N. Yamamoto | H. Osumi | Y. Imamura | K. Yamaguchi | T. Wakatsuki | E. Shinozaki | M. Ogura | K. Shimozaki | A. Ooki | I. Nakayama | Masayuki Watanabe | K. Chin